Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses (2017 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Other Operating Expenses for 12 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Operating Expenses changed N/A year-over-year to $1.9 million, compared with a TTM value of $4.7 million through Dec 2025, down 97.69%, and an annual FY2024 reading of $200.0 million, changed N/A over the prior year.
  • Other Operating Expenses was $1.9 million for Q4 2025 at Agios Pharmaceuticals, up from $1.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $200.0 million in Q3 2024 and bottomed at -$9.8 million in Q4 2022.
  • Average Other Operating Expenses over 5 years is $13.5 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Other Operating Expenses skyrocketed 200100.0% in 2021, then crashed 471.66% in 2022.
  • Year by year, Other Operating Expenses stood at $2.6 million in 2021, then plummeted by 471.66% to -$9.8 million in 2022, then surged by 106.45% to $633000.0 in 2023, then surged by 31495.58% to $200.0 million in 2024, then crashed by 99.06% to $1.9 million in 2025.
  • Business Quant data shows Other Operating Expenses for AGIO at $1.9 million in Q4 2025, $1.7 million in Q2 2025, and $1.1 million in Q1 2025.